A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease (DED)

Trial Profile

A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease (DED)

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Isunakinra (Primary)
  • Indications Dry eyes; Ocular pain
  • Focus Registrational; Therapeutic Use
  • Acronyms OASIS
  • Sponsors Eleven Biotherapeutics
  • Most Recent Events

    • 29 Apr 2016 According to an Eleven Biotherapeutics media release, data from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting.
    • 18 May 2015 Co-primary endpoint has not been met. (total OSDI score), as repoerted in Eleven Biotherapeutics media release.
    • 18 May 2015 Top-line results published in the Eleven Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top